
- 2023.05.29
- IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
- 2023.05.10
- Onconova Therapeutics announces presentation of an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in RDEB-associated SCC at the ISID International Epidermolysis Bullosa Symposium in Osaka
- 2023.04.27
- Analyst Report[Flash report] (Shared Research)
- 2023.04.27
- Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
- 2023.04.24
- SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
- 2023.04.14
- Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
- 2023.04.14
- Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
- 2023.03.24
- Notice of Shareholder Voting Results for the 18th Annual General Meeting of Shareholders
- 2023.03.23
- Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
- 2023.03.23
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2023.03.23
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2023.03.22
- Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)
- 2023.03.01
- Information on Shareholders' Meeting: Updated the Page
- 2023.02.22
- Notification of Amendment to the Articles of Incorporation
- 2023.02.09
- Analyst Report[Flash report] (Shared Research)
- 2023.02.09
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated)
- 2023.02.09
- Notice concerning non-operating expenses
- 2023.01.23
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2023.01.16
- Analyst Report[Follow-up Report] (Fair Research)
- 2022.12.26
- SymBio files lawsuit against Pfizer Japan Inc. for infringement of TREAKISYM patents
- 2022.12.19
- SymBio enters into Sponsored Research Agreement for non-clinical study to verify the effectiveness of brincidofovir in a virus-infected brain tissue model
- 2022.12.16
- SymBio files lawsuit for infringement of TREAKISYM patents
- 2022.12.14
- SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV in Australia
- 2022.12.13
- Presentation on the Anti-lymphoma Activity of Brincidofovir at the 64th ASH Annual Meeting
- 2022.12.12
- Analyst Report[Full report] (Shared Research)
- 2022.11.24
- SymBio enters into Material Transfer Agreement with Penn State College of Medicine for a non-clinical study to evaluate the efficacy of brincidofovir in a polyomavirus model
- 2022.11.08
- Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.11.08
- Revision to Earnings Forecast for FY 2022
- 2022.09.27
- Chimerix announces closing of brincidofovir sale to Emergent BioSolutions
- 2022.08.31
- Notice of Appointment of Corporate Officer
- 2022.08.22
- SymBio submits clinical trial notification to TGA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation in Australia
- 2022.08.09
- The National Institute of Neurological Disorders and Stroke and SymBio Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of brincidofovir (BCV) against Epstein Barr virus (EBV)
- 2022.08.05
- Analyst Report[Update report] (Shared Research)
- 2022.08.04
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.08.04
- Revision to Earnings Forecast for FY 2022
- 2022.07.11
- SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM liquid formulation
- 2022.06.16
- Notice of Resignation of Director
- 2022.06.14
- SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
- 2022.06.13
- SymBio announces status of market adoption of the 10-minute Rapid Infusion (RI) administration of the TREAKISYM Liquid Formulation
- 2022.06.08
- Analyst Report[Basic Report] (Fair Research)
- 2022.06.03
- Analyst Report[Full report] (Shared Research)
- 2022.06.01
- Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.05.24
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2022.05.18
- Chimerix announces sale of brincidofovir to Emergent BioSolutions
- 2022.05.16
- Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.05.11
- Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
- 2022.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
- 2022.04.01
- Joint research agreement with the National Cancer Center on rare cancers
- 2022.03.31
- Notice of Renewal of Syndicated Loan Agreement
- 2022.03.30
- Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
- 2022.03.29
- Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
- 2022.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2022.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2022.03.25
- Analyst Report[Full report] (Shared Research)
- 2022.03.09
- Information on Shareholders' Meeting: Updated the Page
- 2022.03.08
- SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
- 2022.03.07
- SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
- 2022.02.28
- SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
- 2022.02.25
- Response to marketing approvals of generic products
- 2022.02.24
- Notification of Amendments to the Articles of Incorporation
- 2022.02.24
- Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
- 2022.02.24
- SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
- 2022.02.10
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2022.02.10
- Notice concerning non-operating expenses
- 2022.02.10
- Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
- 2022.01.31
- Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
- 2022.01.18
- SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
- 2022.01.06
- Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo
- 2021.12.24
- Notice of Appointment of Executive Vice President, Corporate Officer and COO
- 2021.12.20
- Notice of Appointment of Corporate Officer
- 2021.12.06
- Analyst Report[Follow-up Report] (Fair Research)
- 2021.12.03
- Analyst Report[Full report] (Shared Research)
- 2021.11.24
- SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
- 2021.11.11
- Analyst Report[Update report] (Shared Research)
- 2021.11.11
- Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.11.11
- Notice Concerning Non-operating Expenses